Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA approves Medicines Co.’s urinary tract infection drug

Written by: | no-reply@reuters.com | Dated: Tuesday, August 29th, 2017

 

(Reuters) – The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

The drug, Vabomere, was approved to treat adults with cUTI, including pyelonephritis, a potentially life-threatening infection caused by bacteria traveling from the bladder into one or both of the kidneys.

The FDA said it was granting approval of Vabomere to Rempex Pharmaceuticals, a unit of Medicines Co.

Vabomere contains an antibacterial and an inhibitor which deters certain resistance mechanisms used by bacteria.

Shares of Medicines Co. were up over 4 percent at $40.46 in after-hours trading on Tuesday.

 

Reporting by Manas Mishra in Bengaluru

 

Reuters Health source:

http://www.reuters.com/article/us-fda-medicines-idUSKCN1B92UD

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!

Subscribe

Ad Right Bottom

Main Navigation